A comprehensive characterization of acute heart failure with preserved versus mildly
reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure
Long-Term Registry
Aims To perform a comprehensive characterization of acute heart failure (AHF) with
preserved (HFpEF), versus mildly reduced (HFmrEF) versus reduced ejection fraction
(HFrEF). Methods and results Of 5951 participants in the ESC HF Long-Term Registry
hospitalized for AHF (acute coronary syndromes excluded), 29% had HFpEF, 18% HFmrEF,
and 53% HFrEF. Hospitalization reasons were most commonly atrial fibrillation (more
in HFmrEF and HFpEF), followed by ischaemia (HFmrEF), infection (HFmrEF and HFpEF),
worsening renal function (HFrEF), and uncontrolled hypertension (HFmrEF and HFpEF).
Hospitalization characteristics included lower blood pressure, more oedema and higher
natriuretic peptides with lower ejection fraction, similar pulmonary congestion, more
mitral regurgitation in HFrEF and HFmrEF and more tricuspid regurgitation in HFrEF.
In-hospital mortality was 3.4% in HFrEF, 2.1% in HFmrEF and 2.2% in HFpEF. Intravenous
diuretic (similar to 80%) and nitrate (similar to 15%) use was similar but inotrope
use greater in HFrEF (16%, vs. HFmrEF 7.4% vs. HFpEF 5.3%). Weight loss and estimated
glomerular filtration rate improvement were greater in HFrEF, whereas reduction in
natriuretic peptides was similar. Over 1 year post-discharge, events per 100 patient-years
(95% confidence interval) in HFrEF versus HFmrEF versus HFpEF were: all-cause death
22 (20-24) versus 17 (14-20) versus 17 (15-20); cardiovascular (CV) death 12 (10-13)
versus 8.6 (6.6-11) versus 8.4 (6.9-10); non-CV death 2.4 (1.8-3.1) versus 3.3 (2.1-4.8)
versus 4.5 (3.5-5.9); all-cause hospitalization 48 (45-51) versus 35 (31-40) versus
42 (39-46); HF hospitalization 29 (27-32) versus 19 (16-22) versus 17 (15-20); and
non-CV hospitalization 7.7 (6.6-8.9) versus 9.6 (7.5-12) versus 15 (13-17). Conclusion
In AHF, HFrEF is more severe and has greater in-hospital mortality. Post-discharge,
HFrEF has greater CV risk, HFpEF greater non-CV risk, and HFmrEF lower overall risk.